What is Simergent?
Simergent is dedicated to revolutionizing home dialysis care, particularly for emerging markets like China, India, and Mexico. The company's flagship product, the Archimedes system, is an affordable automated peritoneal dialysis device engineered to enhance patient mobility and comfort. By enabling individuals to maintain a more normal lifestyle during treatment, Simergent addresses a critical unmet need in the healthcare sector. The device incorporates patented technology aimed at reducing peritonitis rates and simplifying user training, making advanced dialysis more accessible and manageable.
How much funding has Simergent raised?
Simergent has raised a total of $2.8M across 1 funding round:
Angel/Seed
$2.8M
Angel/Seed (2019): $2.8M, investors not publicly disclosed
What's next for Simergent?
The recent major strategic investment positions Simergent for significant scaling and market penetration. With a focus on affordability and patient-centric design, the company is poised to expand its reach in key emerging markets. Future growth will likely involve further product refinement, strategic partnerships to enhance distribution, and continued clinical validation to solidify its position as a leader in home dialysis solutions. This capital infusion is expected to accelerate Simergent's mission to improve the quality of life for dialysis patients globally.
See full Simergent company page
